Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013–2014)

Diagnostic Microbiology and Infectious Disease

Volumn 88, Issue 2, 2017, Pages 177-183

  Pfaller, M A ^a,b   Flamm, R K ^a   Duncan, L R ^a   Mendes, R E ^a   Jones, R N ^a   Sader, H S ^a  

^a JMI LABORATORIES   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Acinetobacter spp; antimicrobial resistance; Cefoperazone sulbactam; China; Enterobacteriaceae; Stenotrophomonas maltophilia; tigecycline

Indexed keywords

AMIKACIN; CEFOPERAZONE PLUS SULBACTAM; CEFTAZIDIME; CEFTRIAXONE; COLISTIN; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; ANTIINFECTIVE AGENT; CEFOPERAZONE; MINOCYCLINE; SULBACTAM;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG SCREENING; ESCHERICHIA COLI; GEOGRAPHICAL VARIATION (SPECIES); GRAM NEGATIVE BACTERIUM; INHIBITION KINETICS; KLEBSIELLA PNEUMONIAE; MIC50; MIC90; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA; ANALOGS AND DERIVATIVES; ASIA; CHINA; COMBINATION DRUG THERAPY; DRUG EFFECTS; ENTEROBACTERIACEAE; EUROPE; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST;

ACINETOBACTER; ANTI-BACTERIAL AGENTS; ASIA; CEFOPERAZONE; CHINA; DRUG THERAPY, COMBINATION; ENTEROBACTERIACEAE; EUROPE; GRAM-NEGATIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA; SULBACTAM;

EID: 85015791625     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2017.02.020     Document Type: Article

References (37)

1. Bin, C., Hui, W., Renyuan, Z., Yongzhong, N., Xiuli, X., Yingchun, X., et al. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli. Diagn Microbiol Infect Dis 56 (2006), 351–357.
2. Boucher, H.W., Talbot, G.H., Bradley, J.S., Edwards, J.E., Gilbert, D., Rice, L.B., et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48 (2009), 1–12.
3. CDC, National and State Healthcare-Associated Infections Progress Report. Available at http://www.cdc.gov/HAI/pdfs/progress-report/hai-progress-report-2015.pdf, 2013 [Accessed January 2015].
4. CEFOBID®, Package Insert. 2006, Pfizer, New York, NY [Available at http://www.pfizer.com/files/products/uspi_cefobid.pdf. Accessed March 9, 2016].
5. Chen, Y.H., Lu, P.L., Huang, C.H., Liao, C.H., Lu, C.T., Chuang, Y.C., et al. Trends in the susceptibility of clinically important resistant bacteria to tigecycline: results from the Tigecycline In Vitro Surveillance in Taiwan study, 2006 to 2010. Antimicrob Agents Chemother 56 (2012), 1452–1457.
6. Clinical and Laboratory Standards Institute, M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard- tenth edition. 2015, CLSI, Wayne, PA.
7. Clinical and Laboratory Standards Institute, M100-S26. Performance standards for antimicrobial susceptibility testing: 26th informational supplement. 2016, CLSI, Wayne, PA.
8. DiPersio, J.R., Dowzicky, M.J., Regional variations in multidrug resistance among Enterobacteriaceae in the USA and comparative activity of tigecycline, a new glycylcycline antimicrobial. Int J Antimicrob Agents 29 (2007), 518–527.
9. Draper, M.P., Weir, S., Macone, A., Donatelli, J., Trieber, C.A., Tanaka, S.K., et al. Mechanism of action of the novel aminomethylcycline antibiotic omadacycline. Antimicrob Agents Chemother 58 (2014), 1279–1283.
10. van Duin, D., Bonomo, R.A., Ceftazidime/avibactam and Ceftolozane/tazobactam: Second-generation beta-lactam/beta-lactamase inhibitor combinations. Clin Infect Dis 63 (2016), 234–241.
11. ECDC, Antimicrobial resistance surveillance report Europe. Available at http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2013.pdf, 2013 [Accessed June 2016].
12. EUCAST, Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0. 2016 Available at http://www.eucast.org/clinical_breakpoints/ [Accessed January 2016].
13. Farrell, D.J., Sader, H.S., Flamm, R.K., Jones, R.N., Ceftolozane/tazobactam activity tested against gram-negative bacterial isolates from hospitalized patients with pneumonia in United States and European medical centres (2012). Int J Antimicrob Agents 43 (2014), 533–539.
14. Fass, R.J., Gregory, W.W., D'Amato, R.F., Matsen, J.M., Wright, D.N., Young, L.S., In vitro activities of cefoperazone and sulbactam singly and in combination against cefoperazone-resistant members of the family Enterobacteriaceae and nonfermenters. Antimicrob Agents Chemother 34 (1990), 2256–2259.
15. Hawkey, P., Finch, R., Tigecycline: in-vitro performance as a predictor of clinical efficacy. Clin Microbiol Infect 13 (2007), 354–362.
16. Honeyman, L., Ismail, M., Nelson, M.L., Bhatia, B., Bowser, T.E., Chen, J., et al. Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline. Antimicrob Agents Chemother 59 (2015), 7044–7053.
17. Jones, R.N., Wilson, H.W., Thornsberry, C., Barry, A.L., In vitro antimicrobial activity of cefoperazone-sulbactam combinations against 554 clinical isolates including a review and beta-lactamase studies. Diagn Microbiol Infect Dis 3 (1985), 489–499.
18. Karageorgopoulos, D.E., Kelesidis, T., Kelesidis, I., Falagas, M.E., Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 62 (2008), 45–55.
19. Kelesidis, T., Karageorgopoulos, D.E., Kelesidis, I., Falagas, M.E., Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 62 (2008), 895–904.
20. Klastersky, J., Cefoperazone in the treatment of infections in cancer patients. Am J Med 85 (1988), 9–16.
21. Kollef, M.H., Golan, Y., Micek, S.T., Shorr, A.F., Restrepo, M.I., Appraising contemporary strategies to combat multidrug resistant gram-negative bacterial infections–proceedings and data from the Gram-Negative Resistance Summit. Clin Infect Dis 53:Suppl. 2 (2011), S33–S55 [quiz S6–8].
22. Livermore, D.M., Tigecycline: what is it, and where should it be used?. J Antimicrob Chemother 56 (2005), 611–614.
23. Macone, A.B., Caruso, B.K., Leahy, R.G., Donatelli, J., Weir, S., Draper, M.P., et al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother 58 (2014), 1127–1135.
24. Magill, S.S., Edwards, J.R., Bamberg, W., Beldavs, Z.G., Dumyati, G., Kainer, M.A., et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 370 (2014), 1198–1208.
25. Magiorakos, A.P., Srinivasan, A., Carey, R.B., Carmeli, Y., Falagas, M.E., Giske, C.G., et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18 (2012), 268–281.
26. McLaughlin, J.C., Barry, A.L., Fuchs, P.C., Gerlach, E.H., Hardy, D.J., Pfaller, M.A., In-vitro activity of five beta-lactam/beta-lactamase inhibitor combinations against consecutive isolates of the Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother 33 (1994), 223–230.
27. Micek, S.T., Lloyd, A.E., Ritchie, D.J., Reichley, R.M., Fraser, V.J., Kollef, M.H., Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 49 (2005), 1306–1311.
28. Perez, F., Villegas, M.V., The role of surveillance systems in confronting the global crisis of antibiotic-resistant bacteria. Curr Opin Infect Dis 28 (2015), 375–383.
29. Reitberg, D.P., Whall, T.J., Chung, M., Blickens, D., Swarz, H., Arnold, J., Multiple-dose pharmacokinetics and toleration of intravenously administered cefoperazone and sulbactam when given as single agents or in combination. Antimicrob Agents Chemother 32 (1988), 42–46.
30. Roberts, M.C., Tetracycline therapy: update. Clin Infect Dis 36 (2003), 462–467.
31. Sader, H.S., Flamm, R.K., Jones, R.N., Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011). Diagn Microbiol Infect Dis 76 (2013), 217–221.
32. Sader, H.S., Farrell, D.J., Flamm, R.K., Jones, R.N., Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clincial use (2006 to 2012). Antimicrob Agents Chemother 58 (2014), 2274–2280.
33. Sulperazone®, Package Insert. 2009, Pfizer, Inc., Makati City, Phillipines [Available at http://www.thefilipinodoctor.com/brand_pdf/Sulperazone.pdf. Accessed March 9, 2016].
34. Tumbarello, M., Sanguinetti, M., Montuori, E., Trecarichi, E.M., Posteraro, B., Fiori, B., et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 51 (2007), 1987–1994.
35. Tygacil, Tygacil ® Package Insert. 2016, Wyeth Pharmeceuticals, Philadelphia, PA [Available at www.tygacil.com. Accessed April, 20, 2016].
36. Walsh, T.R., Toleman, M.A., The emergence of pan-resistant Gram-negative pathogens merits a rapid global political response. J Antimicrob Chemother 67 (2012), 1–3.
37. Zhang, D., Micek, S.T., Kollef, M.H., Time to appropriate antibiotic therapy is an independent determinant of postinfection ICU and hospital lengths of stay in patients with sepsis. Crit Care Med 43 (2015), 2133–2140.